DOVA - Dova Pharmaceuticals: Analysis Of Doptelet's Potential In Various Thrombocytopenias
Dova Pharmaceuticals (DOVA) was founded in 2016, and is based in Durham, North Carolina. In this article, I will analyze Dova’s product pipeline and present my investment thesis for this company.
The company’s lead product is Doptelet (avatrombopag), an oral, thrombopoietin receptor agonist (TPO-RA), which received FDA approval for treating chronic idiopathic thrombocytopenia, ITP (low platelet count), in adults who had an inadequate response to previous therapy on June 27. Doptelet was earlier FDA-approved for treating thrombocytopenia in adult patients with chronic liver disease, CLD, who are scheduled to undergo a surgical procedure